89BIO INC (ETNB) Stock Price, Quote, News and Overview
NASDAQ:ETNB - Nasdaq - US2825591033 - Common Stock - Currency: USD
ETNB Quote, Performance and Key Statistics
NASDAQ:ETNB (2/26/2025, 12:34:08 PM)
9.355
+0.13 (+1.46%)
The current stock price of ETNB is 9.355 USD. In the past month the price increased by 2.44%. In the past year, price decreased by -26.94%.
ETNB Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.05 | 358.60B | ||
| AMGN | AMGEN INC | 15.53 | 165.29B | ||
| GILD | GILEAD SCIENCES INC | 24.02 | 137.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1666.38 | 124.15B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.52 | 77.43B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.19B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.12B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.80B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.16B | ||
| NTRA | NATERA INC | N/A | 21.38B | ||
| BIIB | BIOGEN INC | 8.51 | 20.43B | ||
| GMAB | GENMAB A/S -SP ADR | 24.44 | 14.44B |
Related stock screener links
About ETNB
Company Profile
89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company is headquartered in San Francisco, California and currently employs 70 full-time employees. The company went IPO on 2019-11-11. The firm is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone. The company conducted a Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics (PK) of pegozafermin.
Company Info
89BIO INC
142 Sansome Street, Second Floor
San Francisco CALIFORNIA 94104 US
CEO: Rohan Palekar
Employees: 70
Company Website: https://www.89bio.com/
Investor Relations: https://ir.89bio.com/
Phone: 14154329270
89BIO INC / ETNB FAQ
What is the stock price of 89BIO INC today?
The current stock price of ETNB is 9.355 USD. The price increased by 1.46% in the last trading session.
What is the ticker symbol for 89BIO INC stock?
The exchange symbol of 89BIO INC is ETNB and it is listed on the Nasdaq exchange.
On which exchange is ETNB stock listed?
ETNB stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for 89BIO INC stock?
15 analysts have analysed ETNB and the average price target is 31.28 USD. This implies a price increase of 234.37% is expected in the next year compared to the current price of 9.355. Check the 89BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is 89BIO INC worth?
89BIO INC (ETNB) has a market capitalization of 1.24B USD. This makes ETNB a Small Cap stock.
How many employees does 89BIO INC have?
89BIO INC (ETNB) currently has 70 employees.
What are the support and resistance levels for 89BIO INC (ETNB) stock?
89BIO INC (ETNB) has a support level at 9.21 and a resistance level at 11.1. Check the full technical report for a detailed analysis of ETNB support and resistance levels.
Should I buy 89BIO INC (ETNB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ETNB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ETNB, evaluating the profitability, health, valuation and growth aspects
- 89BIO INC (ETNB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- 89BIO INC (ETNB) Sales and EPS estimates to see what analysts future expectations are.
- 89BIO INC (ETNB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- 89BIO INC (ETNB) Insider and Institutional Ownership to learn about the owners and their transactions.
- 89BIO INC (ETNB) Stock Chart to make your own analysis
- 89BIO INC (ETNB) Latest news and press-releases to stay up to date.
Does 89BIO INC (ETNB) stock pay dividends?
ETNB does not pay a dividend.
When does 89BIO INC (ETNB) report earnings?
89BIO INC (ETNB) will report earnings on 2025-03-19, after the market close.
What is the Price/Earnings (PE) ratio of 89BIO INC (ETNB)?
89BIO INC (ETNB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.91).
What is the Short Interest ratio of 89BIO INC (ETNB) stock?
The outstanding short interest for 89BIO INC (ETNB) is 6.45% of its float. Check the ownership tab for more information on the ETNB short interest.
ETNB Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to ETNB. When comparing the yearly performance of all stocks, ETNB is a bad performer in the overall market: 77.02% of all stocks are doing better.
ETNB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ETNB. The financial health of ETNB is average, but there are quite some concerns on its profitability.
ETNB Financial Highlights
Over the last trailing twelve months ETNB reported a non-GAAP Earnings per Share(EPS) of -2.91. The EPS decreased by -46.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -63.05% | ||
| ROE | -76.42% | ||
| Debt/Equity | 0.09 |
ETNB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to ETNB. The Buy consensus is the average rating of analysts ratings from 15 analysts.